{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:39:11Z","timestamp":1762875551815,"version":"build-2065373602"},"reference-count":23,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:00:00Z","timestamp":1378252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The objective of this meta\u2010analysis in patients with myeloma was to test the hypothesis that the addition of bortezomib to induction therapy not only improves the depth of response but also improves post\u2010transplant progression\u2010free survival (PFS) and overall survival (OS) outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Phase 3 trials that randomized newly diagnosed, transplant\u2010eligible patients with myeloma to receive either a bortezomib\u2010containing induction regimen (BCIR) or a nonbortezomib\u2010containing induction regimen (NBCIR) were identified. Preferred Reporting Items for Systematic Reviews and Meta\u2010Analyses (PRISMA) guidelines were adapted for data synthesis, and comprehensive meta\u2010analysis software was used to report pooled data as hazard ratios or odds ratios under a random\u2010effects model.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Four published phase 3 trials that included 2169 patients were analyzed. The postinduction and post\u2010transplant pooled odds ratio for achieving a complete response\/near complete response or a very good partial response or better and the overall response rate were higher with BCIR. The pooled hazard ratios for 3\u2010year PFS and OS were 0.71 (95% confidence interval, 0.60\u20100.83; <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.00,001) and 0.79 (95% confidence interval, 0.66\u20100.96; <jats:italic>P<\/jats:italic>\u2009=\u2009.014), respectively, favoring BCIR. The odds of developing selected grade \u22653 toxicities (peripheral neuropathy and varicella\u2010zoster virus reactivation) also were higher with BCIR.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The current meta\u2010analysis demonstrated that BCIR results in an improved depth of response, which translates into improved post\u2010transplant PFS and OS outcomes despite a higher incidence of toxicity. This analysis supports the concept that the choice of induction regimen can influence post\u2010transplant outcomes such as PFS and OS. <jats:bold><jats:italic>Cancer<\/jats:italic> 2013<\/jats:bold>;119:4119\u20134128. \u00a9 <jats:italic>2013 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28325","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T13:53:51Z","timestamp":1378302831000},"page":"4119-4128","source":"Crossref","is-referenced-by-count":35,"title":["Bortezomib\u2010containing induction regimens in transplant\u2010eligible myeloma patients"],"prefix":"10.1002","volume":"119","author":[{"given":"Ajay K.","family":"Nooka","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhusmita","family":"Behera","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Langston","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charise","family":"Gleason","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.3087"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1853"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11644"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-334755"},{"key":"e_1_2_7_10_1","article-title":"Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front\u2010line therapy for patients with multiple myeloma (MM): initial results of a phase 1 study [abstract]","volume":"116","author":"Kaufman JL","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-300863"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379164"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408898"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1173"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28325","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:27:15Z","timestamp":1760264835000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28325"}},"subtitle":["A meta\u2010analysis of phase 3 randomized clinical trials"],"short-title":[],"issued":{"date-parts":[[2013,9,4]]},"references-count":23,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1002\/cncr.28325"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28325","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2013,9,4]]}}}